These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 515396)

  • 1. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)].
    Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M
    Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396
    [No Abstract]   [Full Text] [Related]  

  • 2. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
    Khader Z
    Nucl Med Commun; 1995 Apr; 16(4):306. PubMed ID: 7542759
    [No Abstract]   [Full Text] [Related]  

  • 11. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Palliative pain relief treatment for multiple bone metastases by strontium-89].
    Nishio M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():581-5. PubMed ID: 22208048
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT; Davis LP
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [89-Strontium for painful osteoblastic metastases].
    Golan H; Ratz D
    Harefuah; 1995 May; 128(10):650-4. PubMed ID: 7541384
    [No Abstract]   [Full Text] [Related]  

  • 17. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.